Key result
Hypertrophic cardiomyopathy in children has diverse etiologies, with surgical treatment and implantable cardioverter-defibrillators remaining effective for managing symptoms and preventing sudden cardiac death.
Answers are grounded in this paper and cite their sources.
Surgical treatment and ICDs are effective for managing pediatric hypertrophic cardiomyopathy and preventing sudden cardiac death, with new risk prediction models aiding patient selection.
Hypertrophic cardiomyopathy (HCM) characterized by asymmetric ventricular septal hypertrophy, is the commonest cause of sudden cardiac death (SCD) in the young. The underlying etiology of HCM in the childhood and adolescent patients is diverse. Moreover, the prognosis of pediatric HCM depends on the age of presentation and etiology. Despite the complexity of children with obstructive HCM, surgical treatment results in a favorable outcome for carefully selected patients in experienced tertiary referral center in contemporary era. Implantable cardioverter-defibrillator (ICD) remains the most effective and reliable treatment to prevent SCD. New pediatric SCD risk prediction model, which has good discrimination and calibration and can distinguish patients who are most benefit from an ICD implantation, is expected to be further refined in the future.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a review in Hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy in children has diverse etiologies, with surgical treatment and implantable cardioverter-defibrillators remaining effective for managing symptoms and preventing sudden cardiac death.
Synapse has enriched 10 related papers. Consider them for comparative context: